Skip to main content
Top
Published in: Current Treatment Options in Oncology 5/2024

20-04-2024 | Prostate Cancer | Correction

Correction to: Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer

Authors: Andrew M. Fang, MD, Jamaal Jackson, MD, Justin R. Gregg, MD, Lisly Chery, MD, Chad Tang, MD, Devaki Shilpa Surasi, MBBS, CMQ, Bilal A. Siddiqui, MD, Soroush Rais-Bahrami, MD, MBA, Tharakeswara Bathala, MD, MBBS, Brian F. Chapin, MD

Published in: Current Treatment Options in Oncology | Issue 5/2024

Login to get access

Excerpt

Correction to: Current Treatment Options in Oncology (2024) 25:66-83
Metadata
Title
Correction to: Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer
Authors
Andrew M. Fang, MD
Jamaal Jackson, MD
Justin R. Gregg, MD
Lisly Chery, MD
Chad Tang, MD
Devaki Shilpa Surasi, MBBS, CMQ
Bilal A. Siddiqui, MD
Soroush Rais-Bahrami, MD, MBA
Tharakeswara Bathala, MD, MBBS
Brian F. Chapin, MD
Publication date
20-04-2024
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 5/2024
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-024-01208-1

Other articles of this Issue 5/2024

Current Treatment Options in Oncology 5/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine